U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07167329) titled 'Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial' on Jan. 25.
Brief Summary: The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.
Study Start Date: Jan. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Von Hippel Lindau
Von Hippel Lindau Disease
Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Hemangioblastoma (HB) of the Central Nervous System (CNS)
PNET
Retina...